FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Britain Courts Anthropic Amid US Defense Department Dispute 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SAN DIEGO, Oct. 20, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it has issued inducement awards to two new non-executive employees.
TRACON issued the awards on October 17, 2016 and October 19, 2016. The inducement awards consist of options to purchase an aggregate of 25,740 shares of the Company's common stock and a restricted stock unit award for an aggregate of 9,750 shares of the Company's common stock, and were granted in accordance with NASDAQ Listing Rule 5635(c)(4) under the TRACON Pharmaceuticals, Inc. 2015 Equity Incentive Plan (the "2015 Plan”). Each option has an exercise price per share equal to the closing price of one TRACON share on the Nasdaq Global Market on the dates of grants. The options vest over four years, with 25% of the option shares vesting on the first anniversary of the date of grant and the remaining 75% of the option shares vesting in monthly installments over the three years thereafter. The options have a ten-year term, and are subject to the terms and conditions of the 2015 Plan and applicable stock option agreement. The restricted stock unit vests over four years, with 25% of the shares vesting on the first four anniversary dates of the date of grant. The restricted stock unit is subject to the terms and conditions of the 2015 Plan and applicable restricted stock unit agreement.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
